In this article, we will discuss Pemigatinib (Dosage Overview). So, let’s get started.
Pemigatinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Select patients for the treatment of locally advanced or metastatic cholangiocarcinoma with Pemigatinib based on the presence of an FGFR2 fusion or rearrangement as detected by an FDA-approved test.
The recommended dosage of Pemigatinib is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy, in 21-day cycles. Continue treatment until disease progression or unacceptable toxicity occurs.
Take Pemigatinib with or without food at approximately the same time every day.
Swallow tablets whole. Do not crush, chew, split, or dissolve tablets.
If the patient misses a dose of Pemigatinib by 4 or more hours or if vomiting occurs, resume dosing with the next scheduled dose.